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In the general ageing population, 40% of deaths occur following a prolonged trajectory of
“progressive dwindling,” characterised by chronic accumulation of disability and frailty, and
associated with increased dependency and reduced reserves. Those who progressively
dwindle are poorly catered for by current healthcare systems and would benefit from a coor-
dinated approach to their medical and social care, known as formative care. People with
multiple sclerosis (pwMS) may be more likely to progressively dwindle, and may be appro-
priate targets for formative care pathways.
Objectives
To determine the proportion of pwMS who follow a progressive dwindling trajectory prior to
death. To relate trajectory to place of death, and examine what factors predict the progres-
sively dwindling trajectory.
Methods
A retrospective observational study of 582 deceased pwMS enrolled in the UK MS Tissue
Bank, including death certificates and extensive clinical summaries.
Results
73.7% of pwMS had a “progressively dwindling” trajectory of dying. This was predicted by
those who reach MS disease milestones earlier. 72.5% of pwMS died an MS-related death,
which was predicted by an aggressive disease course from onset. Those who progressively
dwindled were equally likely to die in hospital as those with other trajectories to death.
Conclusions
The progressively dwindling trajectory of dying is very common in pwMS, and can be pre-
dicted by earlier disease milestones. Pathways could target pwMS in these years prior to
death, to improve care.
PLOS ONE | DOI:10.1371/journal.pone.0159210 July 21, 2016 1 / 12
a11111
OPEN ACCESS
Citation: Martin JE, Raffel J, Nicholas R (2016)
Progressive Dwindling in Multiple Sclerosis: An
Opportunity to Improve Care. PLoS ONE 11(7):
e0159210. doi:10.1371/journal.pone.0159210
Editor: Francesco Ria, Universitá Cattolica del S.
Cuore, ITALY
Received: January 19, 2016
Accepted: June 28, 2016
Published: July 21, 2016
Copyright: © 2016 Martin et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Raw data has not been
provided as it contains patient identifiable information,
and is custody of the UK MS Tissue Bank. Requests
for data can be made to the UK MS Tissue Bank via
Dr Richard Nicholas (r.nicholas@imperial.ac.uk).
Funding: Dr. Richard Nicholas is supported by the
National Institute for Health Research.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Over the last century there has been a shift in the commonest causes of death, from acute
causes at a young age, to a substantially lengthened lifespan characterised by a period of pro-
gressive chronic illness before death. [1] Bowman and Meyer (2014) described four broad tra-
jectories of dying in an ageing population: [2]
• 20% are sudden e.g. myocardial infarction;
• 20% of deaths follow a short period of rapid decline after a ‘clear clinical transition’ from
treatable to progressive e.g. cancer;
• 20% occur as a result of acute exacerbations of a progressive long-term disease e.g. chronic
obstructive pulmonary disease;
• 40% of deaths occur following a prolonged period of ‘progressive dwindling’ e.g. Alzheimer’s
disease.
For the first three trajectories, healthcare infrastructure is well established and effective,
with preventative and emergency medicine for the sudden trajectory, palliative care for those
with a short period of rapid decline, and specialist chronic disease management programmes
for those with progressive long-term diseases with acute exacerbations. [2] However, there is a
lack of appropriate pathways for those who ‘progressively dwindle’, with often haphazard
involvement of a wide range of healthcare professionals and services, and thus care can be sub-
optimal. [2] A report from the UK Parliamentary and Health Service Ombudsman in May
2015 found a lack of coordination of care services, delays in referral and inadequate out-of-
hours services have led to poor end of life care for a large number of patients. [3] The report
suggested this could be improved by proper service delivery and organisation. [3] The term
‘formative care’ has been coined to describe the strategy of “enabling the best possible life qual-
ity and experience in the context of a life reframed by frailty and dependency” for progressively
dwindling patients in the time between active treatment and end of life care. [2] Aspects of for-
mative care overlap with palliative care, including symptom relief and home care, although for-
mative care focuses on maximising quality of life rather than quality of death, and takes place
over years rather than weeks or months. Elements of formative care might include access to
regular tailored physiotherapy, occupational therapy visits to the home environment, nutri-
tional support, pathways to determine when packages of care should be escalated and improv-
ing this transition, and rationalising medication, focusing on those that improve quality of life.
Promoting implementation of formative care from an early stage will also allow improved tran-
sition into palliative care, and act as a buffer against difficulties in determining when palliative
care should begin. Identifying markers to predict those who will adopt a progressive dwindling
trajectory will be essential for implementing formative care in a timely manner for these
patients.
People with MS (pwMS) have a prolonged disease course, often 50 years or more. [4] Dis-
ease modifying therapies are available for relapsing MS, but there are currently no licensed
treatments for the progressive phase. As a result, a gap in structured care pathways has arisen
between active treatment and end of life care, in which pwMS may spend a prolonged period
‘progressively dwindling’, with considerable distress associated with decline in physical and
mental function. [5] This period without active treatment but before palliation is not specific to
MS, but is particularly pertinent due to the extended and unpredictable timeframe. It is during
this phase that pwMS could greatly benefit from formative care. Those pwMS who progres-
sively dwindle experience a slow and steady accumulation of disability, resulting in frailty, and
associated with increased dependency and reduced physiologic reserve. [6] This period extends
Progressive Dwindling in Multiple Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0159210 July 21, 2016 2 / 12
for many years before death, during which time there is an increasing burden of care, often
taken on by the family, and punctuated by superimposed illness. As the ever-reducing physio-
logic reserve resets the baseline, there is reduced capacity to cope with said periods of superim-
posed illness, such as pneumonia, and ultimately these present the terminal event. [6] Because
formative care promotes adequate planning of and improved transition to palliative care due to
overlap in techniques, it should also empower patients to choose to die at home, if this is their
wish. To understand how formative care might help pwMS, this study aimed to: (i) determine
the frequency of progressive dwindling in an MS population, (ii) identify factors associated
with progressive dwindling, (iii) determine specific cause of death and whether deaths were




Data were retrospectively collated from a cohort of 582 pwMS who had died between January
1998 and February 2015 inclusive, and had been registered on the UKMS Tissue Bank
(UKMSTB). The UKMSTB is a national scheme to collect post-mortem tissue donated from
pwMS and non-MS controls, as well as death certificate data, clinical summaries and extensive
clinical notes. As of February 2015, the UKMSTB stored post-mortem data on 606 pwMS; all
were included in this study after exclusion of 9 donors without a confirmed tissue diagnosis of
MS, and 15 donors with insufficient data on cause of death. Clinical notes were used to define
the date of symptom onset, progressive disease (defined as a period of at least one year with
gradual disability worsening without relapses), wheelchair use, and death, for all patients. Par-
ticipants with missing data on symptom onset, progression, wheelchair use, and/or place of
death were included in the study, but were excluded from relevant analyses. The UKMSTB has
ethical approval from the London Multicenter Research Ethics Committee (MREC/02/2/39) to
prospectively recruit donors after obtaining written informed consent, and accrue an extensive
clinical summary from medical notes and death certificates as previously described. [7]
Classification of death: Cause, MS-related, Trajectory, and Place
Death certificate entries were used to categorise underlying cause of death (UCD), and con-
firmed using patient notes and clinical summaries when the death certificate was unclear. For
example, if the death certificate stated ‘infection’ or ‘respiratory failure’, clinical notes were
used to identify a more specific UCD e.g. pneumonia. If multiple causes were listed on the
death certificate, clinical notes were used to discern the primary cause of death. If multiple
causes of death were listed, the diagnosis that triggered the chain of events leading to death was
chosen (e.g. pneumonia leading to respiratory failure). Where it could not be discerned
whether one was more responsible that the other (e.g. pneumonia and UTI), and the clinical
notes did not clarify, the first listed was used as the UCD. UCD was only categorised as MS
when no other cause was listed; where possible a more specific cause (e.g. pneumonia) was
used, even if secondary to MS. Deaths were also classified as being ‘related to MS’ or not, by
examining death certificates and clinical notes. Trajectory to death categories were adapted
from Bowman and Meyer; [2] trajectory was based on cause of death and review of the clinical
summaries. Place of death categories were based on Public Health England’s place of death
classification. [8] Own residence, care home and hospice deaths were also combined into a
‘community’ category.
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Statistical analysis
Cox proportional hazards regression was performed to compare survival from disease mile-
stones between different groups e.g. those with MS-related deaths vs. those with non-MS-
related deaths, those who progressively dwindled vs. those with other disease trajectories. Dis-
ease milestones were compared between all four disease trajectory groups using one way
between subject ANOVA, with Tukey HSD used post hoc for significant ANOVA analyses.
Student’s t-test was used to compare demographics in males and females. Parametric tests were
performed after testing for normality. Chi-squared test was used to compare location of death
in those with different trajectories to death, and those with and without MS-related deaths.
Yates’ chi-squared test was used to avoid overestimation of statistical significance. Where chi-
squared revealed significance in contingency tables greater than 2x2, further post hoc 2x2 chi-
squared tests were carried out to identify the significant values, with criteria for statistical sig-
nificance adjusted according to the number of post hoc tests carried out.
Results
Study population and cause of death
582 deceased pwMS were included in the analysis. 70% were female, and the average age at
symptom onset was later among females than males (34.1±10.7 [mean±SD] vs 30.6±9.7
p<0.001). The average age of progression was 45.5±11.3, the average age of wheelchair use was
50.6±12.8 and the average age at death was 63.8±12.7 years with women dying later than men
(64.9±13.1 vs 61.2±11.5, p<0.01). 68.5% were categorised as secondary progressive MS at the
time of death, 11.4% primary progressive, 6.0% relapsing remitting, and the sub-type of MS
was unavailable in 14.1%. The most common UCD was pneumonia or bronchopneumonia
(37.5%), followed by MS (14.8%), cancer (10.1%), and aspiration pneumonia (8.6%; Table 1).
72.5% died an MS-related death. 35.9% of pwMS did not have MS recorded on any part of
Table 1. Cause of death of 582 people with MS, UKMSTB January 1998 to February 2015.
Cause of death speciﬁc categories n (%)
Multiple sclerosis 86 (14.8)
Pneumonia, bronchopneumonia 218
(37.5)
Aspiration pneumonia 50 (8.6)
Urinary tract infection 34 (5.8)
Other infection, inc. sepsis 12 (2.1)
Acute cardiovascular event 22 (3.8)
Acute cerebrovascular event 18 (3.1)
Pulmonary embolism 14 (2.4)
Non-acute cardiac e.g. senile myocardium or heart failure 11 (1.9)
Respiratory failure 9 (1.5)
Infection secondary to chronic obstructive pulmonary disease 7 (1.2)
Cancer 59 (10.1)
Acute abdomen e.g. obstruction 13 (2.2)
Suicide 7 (1.2)
Epilepsy 3 (0.5)
Other e.g. fulminant liver failure, renal failure, dehydration, acute pyelonephritis, tuberculosis,
old age, myelodysplastic syndrome, liver abscess, progressive multifocal leukoencephalopathy,
general deterioration, anaphylactic reaction, cardiac asthenia amyloid, ruptured left subclavian
artery aneurysm, necrotic fasciitis, accidents, dementia, and frailty.
19 (3.1)
doi:10.1371/journal.pone.0159210.t001
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their death certificate; including 28.7% of those whose death was adjudged to be MS-related
after inspection of clinical notes in this study.
MS-related deaths are predicted by markers of aggressive disease
Of the 582 pwMS, 72.5% died an MS-related death. MS-related deaths were associated with
younger age at symptom onset (MS-related: 31.6±9.9; non MS-related 36.9±10.9, p<0.0001),
progression (MS-related: 43.5±10.3; non MS-related 51.3±11.9, p<0.0001), wheelchair use
(MS-related: 48.4±11.9; non MS-related 57.6±12.9, p<0.0001) and death (MS-related: 61.5
±12.4; non MS-related 68.9±11.6, p<0.0001). MS-related deaths were also associated with a
shorter time from symptom onset to death (MS-related: 29.4 ±11.9; non MS-related 32.9±12.7,
p<0.01). These earlier milestones are indicative of more aggressive disease courses leading to
MS-related deaths (Fig 1).
Progressive dwindling is a common trajectory in MS, and is predicted by
earlier disease milestones
Of 582 pwMS, 429 (73.7%) progressively dwindled, 76 died a sudden death, 59 experienced a
clear clinical transition from a treatable to an unrelenting progressive disease (e.g. cancer), and
18 died as a result of an acute exacerbation of a progressive long-term condition. When compar-
ing those who progressively dwindled with the other trajectories combined, those who progres-
sively dwindled had earlier age at onset, progression, wheelchair use and death (all p<0.01; Fig
2). Differences between groups remained when comparing individual groups in a one-way
between subjects ANOVA (Table 2). More specifically, after post-hoc Tukey HSD, those who
progressively dwindled had a mean age at MS onset five years earlier than those who died sud-
denly (p<0.01). Those who experienced a progressive dwindling trajectory had an earlier age at
progression than those who died following a clear clinical transition (p<0.05) or an acute
Fig 1. Cox proportional hazard regression model comparing disease length leading to MS-related
deaths and unrelated deaths. Those whose death was MS-related had a shorter disease course from
symptom onset to death than those whose death was unrelated (R2 = 0.016, n = 504, p<0.01; MS death 1.32,
95CI 1.08–1.61). Dotted line represents MS-related deaths; solid line represents non-MS-related deaths.
doi:10.1371/journal.pone.0159210.g001
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Fig 2. Cox proportional hazard regression models of diseasemilestones in those who progressively dwindle
compared to other trajectories. Those who progressively dwindle had an earlier age at onset (A, R2 = 0.02, n = 504, p<0.01;
Progressive dwindling: 1.08, 95CI 1.03–1.14), progression (B, R2 = 0.024, n = 390, p<0.01; Progressive dwindling: 1.09, 95CI
1.03–1.16), wheelchair use (C, R2 = 0.022, n = 462, p<0.01; Progressive dwindling: 1.09, 95CI 1.03–1.15) and death (D, R2 =
0.014, n = 582, p<0.01; Progressive dwindling: 1.07, 95CI 1.02–1.12). Dotted lines represent those with progressive dwindling
trajectory to death; solid line represents all other disease trajectories.
doi:10.1371/journal.pone.0159210.g002
Table 2. Different Trajectories association with MSmilestones.
Trajectories Mean age at symptom
onset ±SD (n)
Mean age at progression
±SD (n)
Mean age at wheelchair
±SD (n)
Mean age at death
±SD (n)
Clear clinical transition 35.3±10.0 (54) 50.2 ±9.9 (38) 54.2±10.6 (39) 67.7±10.2 (59)
Acute exacerbation of progressive long-
term condition
35.5±10.4 (15) 54.5±15.3 (12) 58.5±13.6 (13) 71.2±9.2 (18)
Sudden 36.9±10.7 (65) 47.1±10.4 (42) 54.4±13.0 (56) 66.5±12.1 (76)
Progressive dwindling 32.0±10.3 (370) 44.3±11.1 (298) 49.3±12.6 (354) 62.5±13.0 (429)
ANOVA Signiﬁcance p<0.01a p<0.001a p<0.001a p<0.001a
aThe signiﬁcant associations as identiﬁed by post-hoc Tukey HSD are detailed under ‘Progressive dwindling is a common trajectory in MS, and is predicted
by earlier disease milestones’.
doi:10.1371/journal.pone.0159210.t002
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exacerbation (p<0.01). Those who experienced a progressive dwindling course were wheelchair-
bound 9 years earlier than those who died following acute exacerbations and 5 years earlier than
those who died suddenly (both p<0.05). Those who progressively dwindled died at a younger
age than those who experienced any other trajectory to death (all p<0.05). There was no signifi-
cant relationship between the trajectory to death and interval from symptom onset to death.
Location of death
Of 582 donors included in the study, place of death was available for 503 donors (86.4%). Of
those, 50.7% died in hospital, 25.4% died in a care home, 18.9% died in their own residence,
4.6% died in a hospice and 2 died in other locations. Those who progressively dwindled were
equally likely to die in hospital as those with other trajectories to death (Table 3).
Similarly, those whose death was MS-related were equally likely to die in hospital as those
whose death was unrelated to MS (Table 4). Those with MS-related deaths were less likely to
die in a hospice—a category dominated by those with cancer-related deaths. Dying in the com-
munity rather than in hospital was not associated with an earlier death or a shorter interval
from symptom onset to death.
Discussion
This study finds rates of progressive dwindling in pwMS far greater than in the general popula-
tion. These results emphasise the extended and unpredictable timeframe between active treat-
ment and end of life care in MS, and the high proportion of pwMS who have prolonged
periods of frailty, dependency, and reduced physiological reserve for many years prior to death.
Those who progressively dwindle are equally likely to die in hospital as those with more acute
Table 3. Community vs. hospital and trajectory to death.
Community n (%)a Hospital n (%) Total
1 Clear clinical transition 33 (61.1) 21 (38.9) 54
2 Acute exacerbations of progressive long-term conditions 3 (23.1) 10 (76.9) 13
3 Sudden 32 (47.8) 35 (52.2) 67
4 Progressive dwindling 178 (48.5) 189 (51.5) 367
Total 246 (49.1) 255 (50.9) 501b
aOwn residence, care home and hospice deaths were combined into a ‘community’ category.
bTwo died in ‘other’ locations which were not classiﬁed into community or hospital.
doi:10.1371/journal.pone.0159210.t003
Table 4. The relationship between place of death and whether a death was MS-related.
MS-related death n (%) Not MS-related death n (%)
1 Own residence 67 (70.5) 28 (29.5)
2 Hospital 184 (72.2) 71 (27.8)
3 Care homes 98 (76.6) 30 (23.4)
4 Hospicea 9 (39.1) 14 (60.9)
5 Otherb 0 2
Total 358 (71.2) 145 (28.8)
aSigniﬁcantly lower numbers of subjects died an MS-related death in hospices compared to those who had a
non MS-related death (p<0.01, χ² test).
bExcluded from χ² test
doi:10.1371/journal.pone.0159210.t004
Progressive Dwindling in Multiple Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0159210 July 21, 2016 7 / 12
trajectories to death, which might be interpreted as a failure of care. This study also finds that
progressive dwindling can be predicted by early markers of aggressive disease in pwMS, sug-
gesting an opportunity for targeted formative care in this subset of patients.
The UKMSTB is a community based scheme where people with MS register during their
lifetime for tissue and clinical data to be collected when they die. Donors are representative of
MS patients nationwide as a result of a national community-based recruitment strategy, with
accurate representation of clinical milestones and MS sub-types confirmed by comparison with
other study populations. [7] One advantage of this large cohort of 582 pwMS is that extensive
clinical summaries are available for each donor, to allow accurate categorisation of disease
milestones, trajectories, and cause of death. In addition, it was possible to include cases regard-
less of whether MS was mentioned on the death certificate, in contrast to previous studies on
mortality in MS. [9, 10] Indeed, in our cohort, MS was not mentioned on the death certificate
in 35.9% of cases, many of which we adjudged to have died an MS-related death after inspec-
tion of clinical records. Furthermore, by manually categorising UCD in each patient, we miti-
gated the effect of heterogeneous death certification technique and coding rule changes which
can lead to inconsistent reporting of UCD within other studies. [10–12]
The most important limitation of this study was that data were retrospectively collated from
clinical records and notes. The required data was not apparent on occasion, for example the
‘date of wheelchair use’may not have been documented, while on other occasions coding of
data required interpretation by the assessor. However, care was taken to formulate standard-
ised rules for coding, and the availability of clinical notes improved reliability of data over
death certificates. Overall, manual determination of these factors was considered to be a
strength of this study as it allowed a more thorough analysis of each case, using the clinical
summary where necessary. Another possible limitation is that cases were included whose
deaths occurred between 1998 and 2015. Standards of care may have changed over this period,
although the results reported in this study appeared consistent over time.
The most common cause of death was pneumonia (46%), followed byMS (14.8%), and cancer
(10.1%). The rates of pneumonia and MS deaths are different to those found in other studies,
[12, 13] however this is due to methodological differences; UCD was only classed as MS where
no other cause was available, in order to allow more specific analysis of cause of death. Diseases
of the respiratory system accounted for 15% of deaths in the UK in 2013 and therefore are far
more common in our MS cohort. [14] Cancer is the most common cause of death among the
general population (29%) followed by diseases of the circulatory system (28%); both much higher
rates than in our cohort. [14] Accidents and suicide accounted for 1.2% of deaths in our sample,
equal to rates in the UK general population in 2013. [14, 15] Although only 14.8% of death certif-
icates directly attributed UCD to MS, 72.5% of deaths were MS-related. Younger age at symptom
onset, wheelchair use, progression and death, as well as a shorter disease course, were all associ-
ated with MS-related death. This earlier achievement of disease milestones and shorter interval
between milestones is suggestive of a more aggressive disease course; those who evade this
aggressive disease course are more prone to the same causes of death as the general population.
This study found that 73.7% of pwMS had a progressively dwindling trajectory prior to
death. This is in contrast to the general ageing population, in which 40% of the population pro-
gressively dwindle. [2] Those who progressively dwindled experienced an earlier age at symp-
tom onset, progression, wheelchair use, and death than those experiencing other trajectories,
indicating that earlier disease milestones predict progressive dwindling.
In 2006, 58% of general population deaths in the UK were in hospital and only 35% of peo-
ple died at home or in a care home, despite 56–74% of people saying they would prefer to die at
home. [16, 17] As a result of this majority preference for dying at home, place of death is often
considered a surrogate marker of the success of end of life care. Of 503 pwMS in this study,
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50.8% died in hospital, 25.4% died in a care home, 18.9% died in their own residence, and 4.5%
died in a hospice, consistent with previous work. [10] Those who died following a progressive
dwindling trajectory were as likely to die in hospital as any other group, a statistic that might
be improved with the implementation of formative care pathways for this group, as the nature
of the trajectory allows time to discuss patient preferences and establish appropriate plans.
Major barriers to dying in the community include poor provision of end of life care services by
general practices, insufficient community nursing staff, poor coordination of services, and lack
of access to home modifications and out-of-hours medicines. [18] MS patients may be more
vulnerable to these service deficiencies, as a result of their comparably young age, complex care
needs and increased rates of cognitive disability. [19] Implementation of a structured package
of formative care, with discussions at various stages of the process, would give pwMS opportu-
nities from an early stage, to communicate how they wish to live, and die, as well as providing a
more suitable and coordinated care network to meet their requirements.
As people approach death, an increasing number of pwMS and their caregivers desire sup-
port from palliative care services either at home or in hospices. [17, 20, 21] In our study, those
who died an MS-related death were far less likely to die in a hospice than those who died a
non-MS related death, suggesting hospice services seldom offer palliative care to those dying of
MS, despite previous research showing similarities between MS and cancer in the prevalence of
palliative-care-related problems, and the need for more palliative care services for pwMS. [22,
23] Even in the general population, it is estimated that 69%-82% of those who die need pallia-
tive care, whereas in our study only 4.6% of pwMS died in a hospice, most of whom also had
cancer. [24] Randomised controlled trials in pwMS have shown that palliative care can improve
patient-reported outcomes, care-giver burden, and are cost-effective. [25–27] Difficulties in
determining prognosis can lead to lack of utilisation of end of life care services by those with
non-malignant diseases as healthcare professionals may be unsure when to begin the transfer
to these services. [28, 29] The use of predictors of progressive dwindling, with a transfer to for-
mative care pathways may improve quality of life for these patients in the progressive stage of
their disease, and because of the overlap in techniques, may increase scope for smooth transi-
tion into palliative care in the home or hospice environment. [29] An ongoing randomised
controlled trial from Solari et al is examining the strengths and limitations of a home-based
end-of-life care approach in people with severe MS; this should provide insight into the impact
of, for example, home pain management services on MS symptoms and health-related quality
of life, an important aspect of formative care. [30]
A qualitative study by Borreani et al. of pwMS, their carers and health professionals, found
that adapting to life with disability was of greater importance than end of life care. [31] The
interventions proposed in response to their findings implied a formative approach, including
domestic support, rehabilitation and psychosocial intervention. [31]
Future work should develop ways to improve the delivery of formative care, assess its accept-
ability, and whether it could be delivered in complex situations. Input from pwMS and their
families is paramount in developing such pathways. Further work could build a quantitative
tool to allow clinicians to assess the exact risk of progressive dwindling for an individual patient
with a specific combination of risk factors. Such a tool might be utilised to deliver formative
care approaches to targeted patient populations, and to evaluate their impact on symptom relief,
quality of life, place of death, cost of healthcare, and benefit to carers and family members.
Conclusion
End of life care has been failing a large number of patients because of uncoordinated services,
lack of communication and lack of identification of people who are dying. [3] Formative care,
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when not properly designated as such can be disjointed and inadequate from the patient and
family’s perspective and unnecessarily expensive from a service provider’s angle. [1] This study
concludes that these failings might impact particularly upon pwMS, as 73.7% of pwMS fol-
lowed the progressively dwindling trajectory to death. A marker of these failings lies in the
finding that pwMS who progressively dwindle are no less likely to die in hospital than those
with other trajectories to death. Ideally, those who progressively dwindle should have lower
rates of hospital deaths, as a result of well-timed discussions, adequate planning and well-coor-
dinated formative and palliative care services. This study aimed to identify factors associated
with progressive dwindling and found that early disease milestones such as age at onset, pro-
gression and wheelchair use can be used as potential predictors, thus allowing timely discus-
sions, a vital step towards providing formative care to those who need it. This study found that
72.5% of pwMS died an MS-related death, and this too was associated with an aggressive early
disease course. The use of predictors of progressive dwindling, with a transfer to formative care
pathways for years prior to death may improve quality of life for patients in the progressive
stage of their disease and their caregivers, and may increase scope for smooth transition into
palliative care in the home or hospice environment. We believe that better coordination of
medical and social care is paramount in the years prior to death but subsequent to active treat-
ment in pwMS and other populations. The results from this study provide a framework on
which to base subsequent carestrategies, and to target those who might benefit most from for-
mative care.
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